Averitas Pharma commercializes Qutenza® in the US

Morristown, New Jersey (ots) - Averitas Pharma, a recently
acquired Grünenthal Group company, announced that it has taken over
the US commercialization of Qutenza® (capsaicin) 8% patch on October
30, after the acquisition of the product by Grünenthal on the same
day. Qutenza® is approved in the US for the management of neuropathic
pain associated with postherpetic neuralgia. A single, 1-hour,
localized treatment with Qutenza® may provide 3 months of relief from
post-shingles nerve pain.

"We're happy to establish Grünenthal's commercial footprint in the
largest pharma market in the world," says Douglas Stefanelli,
President of Averitas Pharma. "With Qutenza®, we have an exciting
opportunity in front of us. There's still a high unmet medical need
in pain management, especially for non-opioid treatments. Our plans
include changing the commercial distribution model for Qutenza® to
provide patients and health care providers with improved access to
the product". To support the Qutenza® commercialization, Averitas
Pharma expects to add new positions in New Jersey and across the
country.

"As a leader in pain research and management, we're dedicated to
bringing solutions for patients with high unmet medical needs.
Qutenza® has a broad neuropathic pain label in Europe and Averitas
Pharma is actively pursuing the regulatory approvals necessary to
support expanding the US label," adds Mark Fladrich, Grünenthal's
Chief Commercial Officer.

About Averitas Pharma - Averitas Pharma aims to be more than just
another pharmaceutical company. We focus on bringing non-opioid pain
relief products to market, keeping treatment prices reasonable, and
making the use of our products efficient for both patients and
physicians. We are located in Morristown, NJ.

About Grünenthal - Grünenthal is an entrepreneurial, science-based
pharmaceutical company specialized in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in
diseases with high unmet medical need by 2022 and become a EUR 2 bn
company. We are a fully integrated research & development company
with a long track record of bringing innovative pain treatments and
state-of-the-art technologies to patients. By sustainably investing
in our R&D above the industrial average, we are strongly committed to
innovation.

Grünenthal is an independent, family-owned company headquartered
in Aachen, Germany. We are present in approx. 30 countries with
affiliates in Europe, Latin America and the US. Our products are sold
in more than 100 countries with approximately 5,200 employees
worldwide. In 2017, Grünenthal achieved revenues of approx. EUR 1.3
bn.

More information: www.grunenthal.com

About Qutenza®

Qutenza® is indicated for the management of neuropathic pain
associated with postherpetic neuralgia.

IMPORTANT SAFETY INFORMATION

Treatment with Qutenza® must be performed only by a healthcare
provider. You should never apply or remove Qutenza® yourself.

Warnings and Precautions:

- Qutenza® is not for use near eyes or mucous membranes. Do not sniff
or inhale near the Qutenza® patch as this may cause you to cough or
sneeze.
- Do not touch the Qutenza® patch with your hands. If you touch the
patch, it may cause burning and stinging; if this occurs, tell your
healthcare provider.
- Even though a numbing medicine is used on the skin before applying
Qutenza®, some patients may still experience substantial pain during
the treatment. Tell your healthcare provider if you are experiencing
pain; a cool compress or medicine for the pain can be provided to
help lessen your discomfort.
- Qutenza® can cause serious side effects including pain and
increases in blood pressure during or right after treatment.
- Your healthcare provider should check your blood pressure during
treatment with Qutenza®.
- Patients who have high blood pressure that is not well controlled
by medicine, or who have had recent heart problems, stroke, or other
vascular problems, may be at increased risk and should discuss with
their doctor whether Qutenza® is right for them.
- If opioids are used to treat pain associated with the application
procedure, please note that opioid treatment may affect the patient's
ability to perform potentially hazardous activities such as driving
or operating heavy machinery.

Side Effects:

- In clinical studies, the most common drug-related side effects of
Qutenza®, which occurred in 5% or more of patients, included redness,
pain, itching, or small bumps where Qutenza® was applied, and nausea.
- You should tell your doctor if any side effects bother you or do
not go away.

These are not all the side effects of Qutenza®. You are encouraged to
report negative side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch, or call 1-800-FDA-1088. For more information,
ask your healthcare provider or pharmacist.

For the full Prescribing Information, please visit www.Qutenza.com.
Qutenza® is a registered US trademark of Averitas Pharma, Inc.
72512-QZ-10

For further information, please contact:
Douglas Stefanelli, President Averitas Pharma, Inc.
phone: 908-745-2271
dstefanelli@averitaspharma.com
Averitas Pharma, Inc. 360 Mt. Kemble Avenue, Morristown, NJ 07960

Original-Content von: Averitas Pharma, übermittelt durch news aktuell